Similarly, but less frequently than in the current cohort, more than half of the patients continued ISs concomitantly to RTX in the EUSTAR SSc cohort; skin, joint manifestations, and CRP levels increased; however, lung function was stabilized after RTX therapy. The gene discussed is CRP; the disease is systemic sclerosis.